MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

Consensus Ratings for Zynerba Pharmaceuticals (NASDAQ:ZYNE) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.60 (385.84% upside)

Analysts' Ratings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Show:
DateFirmActionRatingPrice TargetActions
6/28/2016OppenheimerReiterated RatingBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/7/2016Jefferies GroupReiterated RatingBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2016Roth CapitalInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2016Piper JaffrayReiterated RatingOverweight$42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
5/12/2016        
5/12/2016Q1($0.56)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.29)($0.62)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2015Q3($0.41)($0.44)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.51)($0.43)($0.47)
Q2 20162($0.51)($0.48)($0.50)
Q3 20162($0.64)($0.56)($0.60)
Q4 20162($0.63)($0.54)($0.59)
Q1 20171($0.71)($0.71)($0.71)
Q2 20171($0.71)($0.71)($0.71)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.56)($0.56)($0.56)
(Data provided by Zacks Investment Research)
Dividend History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
DateHeadline
06/29/16 07:22 PMBrokers Issue Average Price Target Of 33.60 On Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard
06/29/16 10:07 AMZynerba Pharma (ZYNE) Reports Positive Top Line Results from ZYN002 CBD Gel Phase 1, Plans Phase 2 Study
06/28/16 07:25 PMZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Earnings Glance and Target Price Review - Engelwood Daily
06/28/16 07:25 PMShare Update and Earnings Review for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph
06/28/16 05:02 AMZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/28/16 04:16 AMStock Volatility in Review: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Engelwood Daily
06/28/16 04:16 AMEquity Research and Technical Review on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Press Telegraph
06/27/16 03:31 PMZynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures - [at noodls] - DEVON, Pa., June 27, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid ...
06/27/16 08:00 AM15 Stocks Moving In Monday's Pre-Market Session - Gainers HeartWare International Inc (NASDAQ: HTWR) rose 91.49 percent to $57.41 in pre-market trading after Medtronic PLC (NYSE: MDT) announced its plans to acquire HeartWare for $58 per share in cash. GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares rose 17.96 percent to $98.27 in pre-market trading following positive Epidiolex results. The company reported that Epidiolex met the primary endpoint in Phase 3 trial. Great Lakes Dredge & Dock Corporation (NASDAQ: GLDD) shares rose 13.56 percent to $5.11 in pre-market trading after dropping 5.46 percent on Friday. Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares rose 9.15 percent to $8.35 in pre-market trading after falling 1.54 percent on Friday. Energy Transfer Equity LP (NYSE: ETE) rose 5.78 percent to $14.63 in pre-market trading after a Delaware judge decided the company could walk away from its $20 billion+ takeover of Williams Companies without a penalty. Skullcandy Inc (NASDAQ: SKUL) shares rose 4.7 percent to ...Full story available on Benzinga.com
06/27/16 04:01 AMZynerba Pharmaceuticals, Inc. (ZYNE) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 07:25 PMRecently Issued Stock Ratings For Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard
06/24/16 07:25 PMShare Volatility Check for: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Press Telegraph
06/23/16 08:17 PMFatty Acid Amide Hydrolase - Pipeline Review, H1 2016 - New Report Available
06/22/16 07:24 PMDoes oral cannabidiol convert to THC, a psychoactive form of cannabinoid, in the stomach?
06/22/16 04:04 AMNew study reveals conversion of oral cannabidiol to THC by acidic fluids in the stomach
06/20/16 06:53 PMThis Weeks Broker Views For Zynerba Pharmaceuticals, Inc. (ZYNE) - Fiscal Standard
06/15/16 07:17 PMZynerba Pharmaceuticals, Inc. (ZYNE) Current Analyst Ratings - Fiscal Standard
06/10/16 07:54 PMMarket of Rett Syndrome Pipeline Reviewed of 14 Companies and 23 Drug Profiles
06/09/16 10:37 AM"Fragile X Syndrome Global Clinical Trials Review, H1, 2016" is now available at Fast Market Research
06/04/16 10:40 AMAnalyst's Overview of Two Stocks: ABIOMED, Inc. (NASDAQ:ABMD) , Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) - Street Updates
06/03/16 06:16 PMWeeding Out the Winners in Race for Cannabis-Based Drugs -
06/03/16 10:35 AMForm 8-K Zynerba Pharmaceuticals, For: May 25
06/02/16 10:50 AMBroker Watchlist: Zynerba Pharmaceuticals, Inc. (ZYNE) - Share Trading News - Broker Watchlist: Zynerba Pharmaceuticals, Inc. (ZYNE)Share Trading News11/12/2015 – Zynerba Pharmaceuticals, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 35 price target on the stock. The share price of Zynerba Pharmaceuticals, Inc. (ZYNE) was up +1.14% during the last trading ...and more »
06/01/16 10:33 AMZynerba Pharmaceuticals Inc (NASDAQ:ZYNE)'s Company Shares Decreased 4.91% After High Volatility - HNN - Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)'s Company Shares Decreased 4.91% After High VolatilityHNNThe shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) decreased by 4.91% in the last 20 days but rose 7.04% in the past 5 trading sessions. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) shares opened at $7.64 in the last session and had intraday ...
06/01/16 06:23 AMZynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences - [at noodls] - DEVON, Pa., June 01, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid ...
05/31/16 07:55 AMStock Review and Earnings Check on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - HNN - Stock Review and Earnings Check on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Zynerba Pharmaceuticals Inc ...and more »
05/30/16 08:52 PMTarget Check and Stock Performance Recap Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - HNN - Target Check and Stock Performance Recap Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)HNNTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Zynerba Pharmaceuticals Inc ...and more »
05/28/16 01:41 PMGlobal Peripheral Neuropathic Pain Therapeutics Pipeline Report 2016 - 10 Companies & Drug Profiles - Research and Markets - ... and Company GW Pharmaceuticals Plc Nektar Therapeutics Phosphagenics Limited Spherium Biomed S.L. Sunovion Pharmaceuticals Inc. Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/bfhjwd/peripheral View ...
05/24/16 12:04 PMTarget Check and Stock Performance Recap Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Wall Street Hints and News - Target Check and Stock Performance Recap Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Zynerba Pharmaceuticals Inc ...and more »
05/24/16 12:04 PMEarnings Review and Stock Rundown for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Wall Street Hints and News - Earnings Review and Stock Rundown for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) ...and more »
05/22/16 12:18 PMZynerba Pharmaceuticals Incorporated (NASDAQ:ZYNE) Shorted Shares Increased By 19.33% - Wall Street Hints and News - Zynerba Pharmaceuticals Incorporated (NASDAQ:ZYNE) Shorted Shares Increased By 19.33%Wall Street Hints and NewsZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The company has a market cap of $64.55 million. The Firm is evaluating ...and more »
05/21/16 12:45 PMStocks to Watch: VWR Corporation (NASDAQ:VWR), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Cabela's ... - KC Register - Stocks to Watch: VWR Corporation (NASDAQ:VWR), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), Cabela's ...KC RegisterZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) reported financial results for the quarter ended March 31, 2016. As of March 31, 2016, cash and cash equivalents were $36.8 million, compared to $41.5 million as of December 31, 2015. Research and ...
05/21/16 12:45 PMRevenue Update on Zynerba Pharmaceuticals Inc(NASDAQ:ZYNE) - Trade Calls - Revenue Update on Zynerba Pharmaceuticals Inc(NASDAQ:ZYNE)Trade CallsZynerba Pharmaceuticals Inc(NASDAQ:ZYNE) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 12, 2016. Company reported revenue of $7.25K. Analysts estimated a revenue of $10.00K. Earnings ...Is it Time to Cash in Profits on Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)Franklin Independentall 3 news articles »
05/20/16 12:04 PMZYNERBA PHARMACEUTICALS, INC. Financials -
05/19/16 07:10 PMETF’s with exposure to Zynerba Pharmaceuticals, Inc. : May 20, 2016 -
05/19/16 12:50 PMStocks in News: Oracle Corporation (NYSE:ORCL), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), GSE Systems Inc ... - KC Register - Stocks in News: Oracle Corporation (NYSE:ORCL), Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), GSE Systems Inc ...KC RegisterZynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) reported financial results for the quarter ended March 31, 2016. As of March 31, 2016, cash and cash equivalents were $36.8 million, compared to $41.5 million as of December 31, 2015. Research and ...
05/17/16 03:39 PMZynerba Pharmaceuticals, Inc. :ZYNE-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 12:39 PMShare Recap and Earnings Focus on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - Wall Street Hints and News - Share Recap and Earnings Focus on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Zynerba Pharmaceuticals Inc ...and more »
05/12/16 11:42 AMBRIEF-Zynerba Pharma Q1 loss per share $0.49 - Reuters - BRIEF-Zynerba Pharma Q1 loss per share $0.49ReutersMay 12 Zynerba Pharmaceuticals Inc. * Expects that existing cash and cash equivalents will fund its research and development programs and operations through 2017. * Zynerba pharmaceuticals reports first quarter 2016 financial results and operational ...
05/12/16 07:06 AMZYNERBA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/12/16 06:17 AMZynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Highlights - [at noodls] - DEVON, Pa., May 12, 2016 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid ...
05/12/16 06:15 AMZynerba reports 1Q loss -
05/12/16 06:10 AM7:10 am Zynerba Pharma reports Q1 results -
05/11/16 11:59 AMConsensus Rating Review for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) - B.O.D.Y Confidential - Consensus Rating Review for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/04/16 11:34 AMZynerba Pharmaceuticals Receives a Buy from Oppenheimer - Analyst Ratings - Zynerba Pharmaceuticals Receives a Buy from OppenheimerAnalyst RatingsAccording to The Fly, oppenheimer analyst Rohit Vanjani reiterated a Buy rating on Zynerba Pharmaceuticals (NASDAQ: ZYNE) today and set a price target of $34. The company's shares opened today at $7.67. Vanjani noted, “We hosted investor meetings ...
05/02/16 12:37 PMInvestors Alert: Zynerba Pharmaceuticals (NASDAQ:ZYNE), First Data (NYSE:FDC), Immersion Corporation (NASDAQ ... - KC Register - Investors Alert: Zynerba Pharmaceuticals (NASDAQ:ZYNE), First Data (NYSE:FDC), Immersion Corporation (NASDAQ ...KC RegisterCanaccord Genuity reissued their buy rating on shares of Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) in a research note published. Other analysts have also recently issued reports about the stock. Jefferies Group reiterated a buy rating and issued a ...
05/02/16 12:37 PMBest Stocks: AMC Entertainment Holdings (NYSE:AMC), Zynerba Pharmaceuticals (NASDAQ:ZYNE), ConocoPhillips ... - KC Register - Best Stocks: AMC Entertainment Holdings (NYSE:AMC), Zynerba Pharmaceuticals (NASDAQ:ZYNE), ConocoPhillips ...KC RegisterAMC Entertainment Holdings, Inc. (NYSE:AMC) reported Total revenues were a first quarter record $766.0 million compared to total revenues of $653.1 million for the three months ended March 31, 2015. AMC Entertainment Holdings, Inc. (NYSE:AMC) ...
04/27/16 12:26 PMZynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Share Rating Recap - B.O.D.Y Confidential - Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Share Rating RecapB.O.D.Y ConfidentialShares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/27/16 08:00 AMCANNAINVESTOR Magazine Top 20 Cannabis Stocks - [Accesswire] - ATLANTA, GA / ACCESSWIRE / April 27, 2016 / CANNAINVESTOR Magazine, is pleased to announce its April/May issue Top 20 Cannabis Stocks and Cannabis Stocks to Watch. Our Top 20 Cannabis Stocks were chosen ...
04/24/16 11:11 AMWhat Next for Zynerba Pharmaceuticals Inc Stock After Today's Huge Decline? - CCH Daily News - What Next for Zynerba Pharmaceuticals Inc Stock After Today's Huge Decline?CCH Daily NewsThe stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is a huge mover today! The stock decreased 2.40% or $0.24 on April 22, hitting $9.75. About 228,136 shares traded hands. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has declined 51.25% ...and more »
About Zynerba Pharmaceuticals

Zynerba Pharmaceuticals logoZynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain. The Company's ZYN002 is the synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear, odorless gel that is designed to provide controlled drug delivery with once- or twice-daily dosing. The Company's ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The transdermal patch is a non-invasive and non-oral dosage form of method of delivery. ZYN001 is a pro-drug, which is a drug administered in an inactive or less active form.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZYNE
  • CUSIP:
Key Metrics:
  • Previous Close: $6.71
  • 50 Day Moving Average: $7.80
  • 200 Day Moving Average: $8.57
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $61.73M
  • Current Quarter EPS Consensus Estimate: $-2.37 EPS
Additional Links:
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha